Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01641042 · ClinicalTrials.gov registry record · Phase 3
Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects
A Phase 3 study of Infections, Meningococcal, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 86
- Enrollment target
- 16
- Study locations
NCT01641042 is a Phase 3 study of Infections, Meningococcal that has completed, run by GlaxoSmithKline. The registered enrollment target is 86 participants, below the 512-participant average among 7 other Infections, Meningococcal trials with a reported enrollment target (83% lower). The trial reports 16 study locations across 3 states.
The verdict
NCT01641042, a Phase 3 study of Infections, Meningococcal, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 86 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new meningococcal vaccine 134612 in subjects with increased risk of meningococcal disease and compare it to its activity in healthy subjects.
Conditions Studied
Interventions
- BIOLOGICAL Meningococcal vaccine GSK134612
Study Locations (16)
California
- GSK Investigational Site - Antioch
- GSK Investigational Site - Daly City
- GSK Investigational Site - Fremont
- GSK Investigational Site - Hayward
- GSK Investigational Site - Oakland
- GSK Investigational Site - Redwood City
- GSK Investigational Site - Roseville
- GSK Investigational Site - Sacramento
- GSK Investigational Site - Sacramento
- GSK Investigational Site - Santa Clara
- GSK Investigational Site - Santa Rosa
- GSK Investigational Site - Vallejo
North Carolina
- GSK Investigational Site - Durham
- GSK Investigational Site - Durham
Other
- GSK Investigational Site - Brno
- GSK Investigational Site - Hradec Králové
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2012-09-10 |
| Est. Completion | 2015-03-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01641042
The ClinicalTrials.gov registry entry for NCT01641042 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 512-participant average among 7 other Infections, Meningococcal trials with a reported enrollment target (83% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Infections, Meningococcal appearing as the primary indexed condition, and to 1 intervention - of which Meningococcal vaccine GSK134612 is the first listed.
NCT01641042 reports 16 study locations spanning 3 distinct geographic areas - top geographies include California, North Carolina, Other.
Frequently Asked Questions
What is clinical trial NCT01641042 about?
NCT01641042 is a clinical study titled "Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects". The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new meningococcal vaccine 134612 in subjects with increased risk of meningococcal disease and compare it to its activity in healthy subjects.
What is the current status of trial NCT01641042?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2012-09-10. Estimated completion is 2015-03-03.
What conditions does trial NCT01641042 study?
This clinical trial studies the following conditions: Infections, Meningococcal.
What interventions are being tested in trial NCT01641042?
The interventions under investigation include: Meningococcal vaccine GSK134612 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01641042?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01641042 being conducted?
This trial has 16 study locations across California, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infections, Meningococcal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014
COMPLETED · Phase 3
-
Safety of 4CMenB Exposure During Pregnancy
COMPLETED
-
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study
COMPLETED
-
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
COMPLETED · Phase 2
-
The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers
COMPLETED · Phase 2
-
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.